Scanning for KRAS, NRAS, BRAF, and PIK3CA Mutations by DNA Melting Analysis with TaqMan Probes

被引:1
|
作者
Botezatu, I. V. [1 ]
Panchuk, I. O. [1 ]
Stroganova, A. M. [1 ]
Senderovich, A. I. [1 ]
Kondratova, V. N. [1 ]
Shelepov, V. P. [1 ]
Lichtenstein, A. V. [1 ]
机构
[1] Blokhin Russian Canc Res Ctr, Res Inst Carcinogenesis, Moscow 115478, Russia
关键词
PCR; mutation scanning; DNA melting; TaqMan probes; multiplex analysis; KRAS; NRAS; BRAF; PIK3CA; CURVE ANALYSIS; SOMATIC MUTATIONS; CANCER; PCR; EGFR; OLIGONUCLEOTIDES; HETEROGENEITY; METASTASIS;
D O I
10.1134/S002689331701006X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Scanning for mutations by DNA melting analysis (DMA) is based on asymmetric PCR followed by the melting of duplexes formed by single-stranded amplicons with TaqMan probes. The method is optimally suited for clinical genetic testing; it is easy to perform, high-throughput, and sensitive. The detection limit of mutant alleles by the DMA method is about 3%, which is much higher than the sensitivity of Sanger sequencing. In addition, the DMA method is realized in a closed-tube format, while 2-h assay is carried out in a single tube without any intermediate or additional procedures thereby minimizing the risk of cross contamination of the samples. The validation of the DMA method was performed by scanning for mutations of clinically significant genes KRAS, NRAS, BRAF, and PIK3CA in 324 DNA samples from tumors of patients with melanoma, colorectal and lung cancer. DNA was isolated either directly from tumor tissues, or from formalin-fixed paraffin-embedded tumor tissues. The detected mutations were verified by Sanger sequencing. The spectra of mutations identified in each tumor type correspond to the literature data and, thus, validate the use of DMA.
引用
收藏
页码:41 / 48
页数:8
相关论文
共 50 条
  • [1] Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes
    I. V. Botezatu
    I. O. Panchuk
    A. M. Stroganova
    A. I. Senderovich
    V. N. Kondratova
    V. P. Shelepov
    A. V. Lichtenstein
    [J]. Molecular Biology, 2017, 51 : 41 - 48
  • [2] Optimization of melting analysis with TaqMan probes for detection of KRAS, NRAS, and BRAF mutations
    Botezatu, Irina V.
    Nechaeva, Irina O.
    Stroganova, Anna M.
    Senderovich, Anastasia I.
    Kondratova, Valentina N.
    Shelepov, Valery P.
    Lichtenstein, Anatoly V.
    [J]. ANALYTICAL BIOCHEMISTRY, 2015, 491 : 75 - 83
  • [3] Analysis of KRAS, NRAS, BRAF and PIK3CA Mutations in Matched Primary and Metastatic Colorectal Carcinomas
    Vakiani, E.
    Janackinaram, M.
    Shia, J.
    Saltz, L.
    Kemeny, N.
    Weiser, M.
    Solit, D.
    [J]. MODERN PATHOLOGY, 2011, 24 : 171A - 171A
  • [4] Analysis of KRAS, NRAS, BRAF and PIK3CA Mutations in Matched Primary and Metastatic Colorectal Carcinomas
    Vakiani, E.
    Janackinaram, M.
    Shia, J.
    Saltz, L.
    Kemeny, N.
    Weiser, M.
    Solit, D.
    [J]. LABORATORY INVESTIGATION, 2011, 91 : 171A - 171A
  • [5] CLINICOPATHOLOGICAL FEATURES OF KRAS, NRAS, BRAF AND PIK3CA MUTATIONS IN JAPANESE PATIENTS WITH MCRC
    Kawazoe, Akihito
    Shitara, Kohei
    Bando, Hideaki
    Kuboki, Yasutoshi
    Kadota, Tomohiro
    Okamoto, Wataru
    Kojima, Takashi
    Fuse, Nozomu
    Yoshino, Takayuki
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [6] Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
    Foltran, Luisa
    De Maglio, Giovanna
    Pella, Nicoletta
    Ermacora, Paola
    Aprile, Giuseppe
    Masiero, Elena
    Giovannoni, Mariella
    Iaiza, Emiliana
    Cardellino, Giovanni Gerardo
    Lutrino, Stefania Eufemia
    Mazzer, Micol
    Giangreco, Manuela
    Pisa, Federica Edith
    Pizzolitto, Stefano
    Fasola, Gianpiero
    [J]. FUTURE ONCOLOGY, 2015, 11 (04) : 629 - 640
  • [7] EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
    Bujko, Mateusz
    Kober, Paulina
    Tysarowski, Andrzej
    Matyja, Ewa
    Mandat, Tomasz
    Bonicki, Wieslaw
    Siedlecki, Janusz Aleksander
    [J]. ONCOLOGY LETTERS, 2014, 7 (06) : 2019 - 2022
  • [8] Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study
    Wojas-Krawczyk, Kamila
    Kalinka-Warzocha, Ewa
    Reszka, Katarzyna
    Nicos, Marcin
    Szumilo, Justyna
    Mandziuk, Slawomir
    Szczepaniak, Katarzyna
    Kupnicka, Dorota
    Lewandowski, Remigiusz
    Milanowski, Janusz
    Krawczyk, Pawel
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (01): : 67 - 73
  • [9] Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
    Takahashi N.
    Yamada Y.
    Taniguchi H.
    Fukahori M.
    Sasaki Y.
    Shoji H.
    Honma Y.
    Iwasa S.
    Takashima A.
    Kato K.
    Hamaguchi T.
    Shimada Y.
    [J]. BMC Research Notes, 7 (1)
  • [10] Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance
    Modos, Orsolya
    Reis, Henning
    Niedworok, Christian
    Ruebben, Herbert
    Szendroi, Attila
    Szasz, Marcell A.
    Timar, Jozsef
    Baghy, Kornelia
    Kovalszky, Ilona
    Golabek, Tomasz
    Chlosta, Piotr
    Okon, Krzysztof
    Peyronnet, Benoit
    Mathieu, Romain
    Shariat, Shahrokh F.
    Hollosi, Peter
    Nyirady, Peter
    Szarvas, Tibor
    [J]. ONCOTARGET, 2016, 7 (26) : 39293 - 39301